Clinical influencing factors of immunotherapy for non-small cell lung cancer
10.3760/cma.j.cn371439-20210927-00149
- VernacularTitle:非小细胞肺癌免疫治疗的临床影响因素
- Author:
Chaoxing LIU
1
;
Xuebing YAN
;
Mengxue YANG
;
Haiyan MAO
;
Jiandong TONG
Author Information
1. 扬州大学附属医院肿瘤科 225000
- Keywords:
Carcinoma, non-small cell lung;
Prognosis;
Anti-bacterial agents;
Immune checkpoint inhibitor
- From:
Journal of International Oncology
2021;48(12):751-754
- CountryChina
- Language:Chinese
-
Abstract:
In the treatment of non-small cell lung cancer (NSCLC), immunotherapies represented by immune checkpoint inhibitors are developing rapidly. It is the premise of precise treatment to clarify the influencing factors of NSCLC immunotherapy. In the course of immunotherapy for advanced NSCLC, elderly patients can obtain specific effect from immunotherapy; male patients benefit more from monotherapy; when steroid hormones are used for related symptoms caused by tumors, they are poor prognostic factors for patients. The occurrence of immune-related adverse events is a favorable prognostic factor while driving gene mutations and the use of antibiotics will reduce the efficacy of immunotherapy.
